Drugs / CHO-A04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07049458 | Dec 2025 → Oct 2027 expected | cancer | Cho Pharma Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHO-A04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07049458 ↗ |
| Route | Intravenous | “CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.” NCT07049458 ↗ |